INMB Inmune Bio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1711754 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY257.1%
TTM net income YoY-9.2%
TTM EPS YoY11.8%
Revenue 3-yr CAGR-48.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-94,766.0%
Net margin-91,866.0%
FCF margin—
EBITDA margin—
Returns
ROE-165.2%
ROA-127.7%
ROIC (approx.)-300.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets27.3%
Debt / equity0.00x
Current ratio3.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.49x
Accruals ratio-64.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | $50,000 | $0 |
| R&D expense | — | — | $3.64M | $2.33M | $4.89M | $5.80M | $7.64M | $7.35M |
| SG&A expense | $1.85M | $2.28M | $2.17M | $3.15M | $2.55M | $2.25M | $2.32M | $2.11M |
| Operating income | -$5.01M | -$1.48M | -$5.81M | -$5.47M | -$7.43M | -$24.57M | -$9.90M | -$9.47M |
| Interest expense | — | — | — | — | — | $250,000 | $0 | $37,000 |
| Net income | -$4.72M | -$1.27M | -$5.41M | -$5.26M | -$6.47M | -$24.46M | -$9.74M | -$9.22M |
| EBITDA | -$4.91M | -$1.38M | -$5.76M | -$5.42M | — | — | — | — |
| EPS (basic) | -0.17 | -0.05 | -0.20 | — | -0.24 | -1.05 | -0.43 | — |
| EPS (diluted) | -0.17 | -0.05 | -0.20 | — | -0.24 | -1.05 | -0.43 | — |
| Weighted avg. shares (diluted) | 27.81M | 26.72M | 26.59M | — | 26.59M | 23.30M | 22.50M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $16.33M | $18.41M | $21.36M | $24.75M | $27.73M | $33.37M | $19.34M | $20.92M |
| Receivables | $1.21M | $4.41M | $479,000 | $4.28M | $1.70M | $1.60M | $1.28M | $1.18M |
| Current assets | $18.71M | $23.80M | $22.82M | $29.89M | $30.67M | $36.03M | $20.96M | $22.66M |
| PP&E, net | $1.19M | $1.26M | $903,000 | $955,000 | $878,000 | $706,000 | — | — |
| Intangibles | — | — | — | — | — | — | $16.51M | $16.51M |
| Total assets | $21.51M | $26.84M | $25.82M | $32.35M | $33.36M | $37.68M | $37.80M | $39.56M |
| Current liabilities | $2.92M | $5.89M | $5.39M | $8.42M | $7.36M | $8.59M | $7.93M | $7.22M |
| Long-term debt | — | — | — | — | — | $15.00M | $15.00M | $15.00M |
| Total debt | — | — | — | — | — | $15.00M | $15.00M | $15.00M |
| Total liabilities | $3.44M | $6.48M | $6.19M | $8.83M | $7.98M | $8.82M | $8.13M | $7.46M |
| Shareholders' equity | $18.07M | $20.36M | $19.62M | $23.52M | $25.38M | $28.87M | $29.67M | $32.10M |
| Net debt | — | — | — | — | — | -$18.37M | -$4.34M | -$5.92M |
| Shares outstanding | 27.92M | 27.65M | 26.59M | 26.59M | 26.59M | 26.59M | 22.93M | 22.28M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.39M | -$3.17M | -$3.40M | -$2.94M | -$5.44M | -$7.38M | -$6.82M | -$11.01M |
| Capital expenditure | — | — | — | $143,000 | $193,000 | — | — | — |
| Free cash flow | — | — | — | -$3.09M | -$5.63M | — | — | — |
| Investing cash flow | $0 | — | — | -$143,000 | -$193,000 | — | — | — |
| Financing cash flow | $1.33M | — | — | $67,000 | $0 | $22.27M | $5.27M | -$2.08M |
| Depreciation & amortization | $100,000 | $100,000 | $52,000 | $56,000 | — | — | — | — |
| Stock-based compensation | $1.12M | $1.36M | $1.50M | $3.32M | $2.98M | $1.53M | $2.08M | $1.76M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.